Quad Technologies Inc (“Quad”), developer of a novel separation technology, has formally announced its entry into the cell separation market. Focused on overcoming barriers associated with conventional cell purification techniques, the company boasts remarkable scientific expertise, a wealth of business experience and comprehensive financial backing. Led by visionary CEO Dr. Sean Kevlahan, the company is currently building on successful manufacturing and feasibility studies of QuickGelÔ, its lead patent-pending technology.
Quad Technologies is set to have initial major impact in the multi-million dollar market of cell separation, addressing the growing frustration amongst researchers with the low viability and efficiency of conventional techniques. These techniques can cause modifications to the cell structure and render it unviable for further development, and can have significant time and cost implications. Quad Technologies’ ground-breaking QuickGel is a dissolvable hydrogel technology that, for the first time, allows researchers to maintain the viability and phenotype of rare isolated cells. The company sees additional near term opportunities in protein purification and nucleic acid extraction.
With our QuickGel technology in hand, Quad is poised for an exciting period of aggressive growth, commented CEO, Sean Kevlahan who developed the technology while undertaking his PhD at Northeastern University. Recent validation of our technology at world class beta test sites affords us great confidence in our go-to market strategy. We are looking forward to seeing the impact of our high value cell separation technology in areas such as stem cell research. Having already been widely published, the product is due to be made available later this year and we expect that it will enable major scientific breakthroughs to be achieved...
Dr. Jeffrey Chalmers, Director of the Ohio State University Medical School Cell Separation Core Facility and Professor of Chemical Engineering, who is a member of Quad Technologies’ scientific advisory board explained:
The initial testing of the QuickGel coated beads that we carried out for Quad Technologies clearly demonstrated the capabilities of the technology in overcoming previously unresolvable issues associated with conventional cell isolation techniques. QuickGel will enable developers of the new generation of therapeutics and diagnostics to achieve higher efficiency, cell viability and purity and I am extremely excited to be involved with the company at this time.
Quad Technologies has secured funding from prominent investors in both the Boston, MA and Houston, TX regions, positioning the company to move forward with its roadmap for the future. Dr. Kevlahan has complemented his strategy and vision for Quad with developing a strong team. Quad Technologies recently appointed Chief Operating Officer Jeff Zonderman who brings 25 years’ experience and proven business acumen in the life science separations markets. Additionally, the company has assembled a growing scientific advisory board and an impressive team of seasoned scientific advisors. In addition to Dr. Chalmers, this team includes Dr. James Coull (biochemist and bio-conjugations expert; founder of Boston Probes and CTO of PNA Innovations) and Dr. Thomas Neenan (polymer chemist and founder of Sideris Pharmaceuticals).